Enterome Bioscience SA and Nestlé Health Science SA are creating a new startup – Microbiome Diagnostics Partners (MDP) – which is poised to focus on the development of a test for inflammatory bowel disease (IBD) and finding additional biomarkers.

Livanova plc has won FDA approval to expand its Vagus nerve stimulation (VNS) therapy to treat patients suffering from epilepsy as young as four years of age with partial onset seizures that are refractory to medications. Previously, the London-based company had approval for its Aspire device to patients ages 12 and older.

Illumina Inc. received FDA approval for its Extended RAS Panel, a next-generation sequencing (NGS) test kit to be used with Amgen Inc.'s colorectal cancer drug, Vectibix. The San Diego-based company's companion diagnostic can run on the Illumina Miseqdx system and will enable U.S. laboratories to help clinicians identify which patients are eligible for treatment of metastatic colorectal cancer (mCRC ) with Vectibix (panitumumab).

Illumina Inc. is set to provide its sequencing cancer companion diagnostic test kit to be used along with Amgen Inc.'s EGFR-targeting drug, Vectibix (panitumumab), which earned a supplemental approval for use as a first-line treatment in wild-type RAS metastatic colorectal cancer patients in combination with FOLFOX and as a monotherapy following disease progression after prior treatment with fluoropyrimidine, oxaliplatin and irinotecan-containing chemotherapy.

Royal Phillips NV is set to acquire Spectranetics Corp. for €1.9 billion ($2.2 billion). The proposed acquisition is the latest in a string of efforts the Amsterdam, the Netherlands-based company has made to strengthen its position in health care. The deal is set to close in 3Q17. Upon news of the proposed deal, shares of the Colorado Springs based-company (NASDAQ:SPNC) were up on Wednesday by about 26.15 percent and trading at $38.35. Philips said the acquisition will further expand and strengthen its image-guided therapy business group, which was bolstered significantly by the company agreeing to...

Royal Phillips NV is set to acquire Spectranetics Corp. for €1.9 billion ($2.2 billion). The proposed acquisition is the latest in a string of efforts the Amsterdam, the Netherlands-based company has made to strengthen its position in health care. The deal is set to close in 3Q17. Upon news of the proposed deal, shares of the Colorado Springs based-company (NASDAQ:SPNC) were up on Wednesday by about 26.15 percent and trading at $38.35.